Neurotransmitter Study Guide

📖 Core Concepts Neurotransmitter – a chemical messenger released by a neuron to influence another cell (neuron, muscle, or gland) across a synapse. Synthesis – usually made in the releasing neuron from abundant precursors (e.g., amino acids → monoamines). Storage – packed into synaptic vesicles at the axon terminal; gasotransmitters (NO, CO) are synthesized on‑demand and not stored. Release – an action potential opens voltage‑gated Ca²⁺ channels; Ca²⁺ influx triggers vesicle exocytosis. Receptor interaction – binding to ionotropic (fast, excitatory/inhibitory) or metabotropic (modulatory) receptors determines the postsynaptic effect. Elimination – (1) Diffusion and astrocytic uptake, (2) Enzyme degradation (e.g., acetylcholinesterase for ACh), (3) Reuptake via transporters. Neurotransmitter criteria (Loewi’s rules): synthesized in the neuron, released on activity, reproduces response when applied, and has a removal mechanism. Major classes – amino‑acid (glutamate, GABA, glycine), monoamine (dopamine, serotonin, NE, epinephrine), peptide, purine (ATP), gasotransmitter (NO, CO). Agonist vs Antagonist – agonist activates a receptor; antagonist blocks activation. Both can act directly (bind receptor) or indirectly (alter synthesis, release, or reuptake). 📌 Must Remember Excitatory vs Inhibitory: Glutamate = primary fast excitatory; GABA = primary fast inhibitory (glycine in spinal cord). Neurotransmitter‐disease links: ↓ Dopamine → Parkinson disease; ↑ Dopamine → schizophrenia/addiction. Dysregulated glutamate → excitotoxicity → stroke, ALS, Alzheimer, epilepsy. GABA alterations → anxiety, epilepsy, insomnia. Key drug mechanisms: Cocaine – blocks dopamine reuptake → prolonged signaling. SSRIs – block serotonin reuptake → ↑ synaptic serotonin. Acetylcholinesterase inhibitors – prevent ACh breakdown → used in myasthenia gravis. Nicotine – direct agonist at nicotinic ACh receptors. Loewi’s four criteria must all be satisfied for a molecule to be labeled a neurotransmitter. Reuptake vs Degradation: Reuptake recycles transmitter; degradation permanently inactivates it. 🔄 Key Processes Synthesis – precursor → enzymatic conversion (e.g., tryptophan → serotonin). Vesicle loading & clustering – transporters pump transmitter into vesicles near the presynaptic membrane. Action‑potential arrival → voltage‑gated Ca²⁺ channels open. Ca²⁺ influx → vesicle docking → exocytosis (kiss‑and‑run or full‑fusion). Diffusion across cleft → binding to postsynaptic receptors (ionotropic → rapid depolarization/hyperpolarization; metabotropic → second‑messenger cascade). Termination – diffusion/astrocytic uptake, enzymatic degradation, or transporter‑mediated reuptake. Drug action flow (agonist/antagonist): Direct agonist → binds receptor → mimics natural transmitter. Partial agonist → binds → sub‑maximal response (e.g., buprenorphine). Inverse agonist → binds → produces opposite effect of the baseline activity. Competitive antagonist → occupies receptor → can be outcompeted by higher agonist concentrations. Indirect agonist → ↑ release or block reuptake (e.g., amphetamine). Indirect antagonist → inhibit synthesis/storage (e.g., reserpine). 🔍 Key Comparisons Excitatory vs Inhibitory neurotransmitters Glutamate ↑ postsynaptic Na⁺/Ca²⁺ influx → depolarization. GABA ↑ Cl⁻ influx (GABAA) or K⁺ efflux (GABAB) → hyperpolarization. Direct vs Indirect agonists Direct: nicotine (binds nAChR). Indirect: amphetamine (promotes dopamine release, blocks reuptake). Reuptake vs Enzyme degradation Reuptake = transporter‑mediated clearance for reuse. Degradation = enzymatic breakdown (e.g., ACh → choline + acetate). Amino‑acid vs Monoamine neurotransmitters Amino‑acids: derived from dietary amino acids, act fast via ionotropic receptors. Monoamines: synthesized from single amino acids, often act on metabotropic receptors. Gasotransmitters vs Classic transmitters Gasotransmitters (NO, CO) are gases, not stored, diffuse directly across membranes. ⚠️ Common Misunderstandings “All neurotransmitters are stored in vesicles.” → NO and CO are synthesized and released on demand. “GABA is always inhibitory.” – early development can have excitatory GABA due to reversed chloride gradient. “Reuptake inhibitors increase synthesis.” – they only block clearance; synthesis rate is unchanged. “Chemical imbalance = depression.” – the model is oversimplified; evidence for serotonin‑centric causation is weak. “Antagonists are the same as inverse agonists.” – antagonists block without activity; inverse agonists suppress basal receptor activity. 🧠 Mental Models / Intuition Calcium = trigger button – without Ca²⁺ influx, vesicle release won’t happen. Synapse as a faucet – synthesis = water supply, vesicles = tank, Ca²⁺ = turn of the knob, receptors = downstream pipe valves. Excitation–Inhibition seesaw – net postsynaptic firing = sum of all excitatory pushes minus inhibitory pulls. Drug‑action “traffic” – agonists add cars onto a road (increase signaling); antagonists put up roadblocks; reuptake blockers close the exit ramp (prolong stay). 🚩 Exceptions & Edge Cases Gasotransmitters (NO, CO) bypass vesicular storage and act via diffusion. False neurotransmitters (e.g., tyramine) resemble true transmitters but produce atypical responses. Retrograde signaling – anandamide released from postsynaptic cell travels backward to modulate presynaptic release. Partial agonists can act as functional antagonists in the presence of full agonists (occupy receptors without maximal activation). 📍 When to Use Which Diagnosing a disorder → match symptom pattern to neurotransmitter dysregulation (e.g., bradykinesia → dopamine loss → consider dopamine agonists). Choosing a drug class: Need rapid increase of synaptic transmitter → reuptake inhibitor (SSRIs, cocaine). Want to prolong action without altering release → enzyme inhibitor (acetylcholinesterase inhibitors). Want to block pathological over‑activation → competitive antagonist (atropine for muscarinic overactivity). Experimental manipulation: Test receptor function → use direct agonist (nicotine) vs antagonist (atropine). Probe storage mechanisms → apply reserpine (blocks vesicular storage). 👀 Patterns to Recognize Excess glutamate → excitotoxicity → look for stroke, seizure, neurodegenerative disease clues. Drug that blocks reuptake → expect prolonged signaling and potential euphoria/addiction (cocaine, SSRIs). Symptoms of motor rigidity + tremor → think dopaminergic neuron loss (Parkinson). Sedation + enhanced GABA activity → presence of benzodiazepine‑like agents or GABA‑A agonists. Peripheral vs central effects – acetylcholine at NMJ (muscle contraction) vs muscarinic receptors in autonomic ganglia (modulatory). 🗂️ Exam Traps Confusing degradation with reuptake – enzymes destroy transmitter; reuptake recycles it. Assuming all monoamines are excitatory – dopamine can be inhibitory depending on receptor subtype. Attributing “chemical imbalance” as the sole cause of depression – the outline stresses criticism of this oversimplification. Mixing up direct vs indirect agonists – e.g., labeling amphetamine a “direct agonist” (it’s indirect). Believing gasotransmitters are stored in vesicles – they are synthesized on demand. Thinking GABA is the only inhibitory transmitter – glycine also provides fast inhibition in the spinal cord. --- Use this guide for a rapid, high‑yield review before your neurobiology exam. Focus on the bolded keywords and the “When to Use Which” decision rules to ace application‑style questions.